September 30, 2024
Roche Acquires Regor’s CDK Inhibitors for $850M to Enhance Breast Cancer Portfolio
Roche, Regor Therapeutics, CDK inhibitors, breast cancer, Genentech, pharmaceutical acquisition, transformative medicines
Moderna Faces Second Consecutive Marketing Breach for Spikevax Vaccine
Moderna, Spikevax, Marketing Breach, COVID-19 Vaccine, Regulatory Compliance
Kezar Life Sciences Suspends Enrollment and Dosing in Phase 2b PALIZADE Trial Due to Safety Concerns
Kezar Life Sciences, PALIZADE trial, zetomipzomib, lupus nephritis, safety concerns, patient deaths, clinical trial halt
J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment
Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment
Cereno’s CS1 Shows Promising Results in Reducing PAH Risks in Phase 2 Trial
Cereno Scientific, CS1, HDAC inhibitor, Pulmonary Arterial Hypertension (PAH), Phase 2 trial, Epigenetic modulation, CardioMEMS HF System, Disease-modifying treatment
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Manipulated Alzheimer’s Trial Data
Cassava Sciences, SEC charges, Alzheimer’s drug, simufilam, manipulated trial data, settlement, misleading statements
Roche’s Gazyva Shows Promising Results in Phase 3 Lupus Nephritis Trial, Paving Way for Expanded Use
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.
Bristol Myers Squibb’s $14 Billion Bet Pays Off: FDA Approves Novel Schizophrenia Drug Cobenfy
Bristol Myers Squibb, Karuna Therapeutics, FDA approval, schizophrenia, Cobenfy, novel treatment, muscarinic receptor, psychiatric medication
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
Cassava Sciences Agrees to $40 Million Settlement with SEC Over Misleading Alzheimer’s Drug Trial Claims
Cassava Sciences, SEC settlement, Alzheimer’s drug trial, misleading claims, data manipulation, simufilam, pharmaceutical fraud